Table 1.
Characteristics of the evaluable patients in the study (N = 32).
| Characteristics | Patients (%) |
|---|---|
| Gender | |
| Male | 25 (78) |
| Female | 7 (22) |
| Stage | |
| III HPV positive | 16 (50) |
| III HPV negative | 7 (22) |
| IV A-B HPV negative | 8 (25) |
| IV C HPV positive | 1 (3) |
| Primary site | |
| Oropharynx | 23 (72) |
| Larynx | 5 (16) |
| Oral Cavity | 3 (9) |
| Hypopharynx | 1 (3) |
| Papilloma Virus (p16) | |
| Positive | 17 (53) |
| Negative/Not done | 15 (47) |
| Smoking | |
| Never smoker | 7 (22) |
| Former smoker | 7 (22) |
| Smoker | 18 (56) |
| Alcohol intake | |
| Never | 9 (28) |
| Former | 2(6) |
| Active occasional-moderate | 19 (59) |
| Active heavy | 2 (6) |
| Treatment | |
| Surgery | 1 (3) |
| Surgery followed by adjuvant radiation | 2 (6) |
| Surgery followed by adjuvant chemoradiation | 1 (3) |
| Definitive radiation | 3 (9) |
| Definitive chemoradiation | 25 (78) |
| Cisplatin | |
| Weekly dose (40 mg/m2) × up to 7 doses | 12 (46) |
| High dose (100 mg/m2) × up to 3 doses | 14 (54) |
| Non applicable | 6 |
Only patients with at least a follow-up sample were included.
HPV human papilloma virus.